Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 6/20 | 0.57 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.50 |
| ▸ | ADK | P55263 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.44 |
| ▸ | ATG7 | O95352 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889285 | 0.88 | POLB (0.58) | METTL3PRMT5POLBENPP1P2RY1 | |
| SCHEMBL26031206 | 0.88 | POLB (0.58) | METTL3PRMT5POLBENPP1P2RY1 | |
| SCHEMBL29487848 | 0.88 | POLB (0.58) | METTL3PRMT5POLBENPP1P2RY1 | |
| 2'-Deoxytubercidin SCHEMBL7872096 | 0.84 | METTL3 (0.57) | METTL3PRMT5ADK | |
| 2'-Deoxytubercidin SCHEMBL13314431 | 0.84 | METTL3 (0.57) | METTL3PRMT5ADK | |
| 2'-Deoxytubercidin SCHEMBL23982116 | 0.84 | METTL3 (0.57) | METTL3PRMT5ADK | |
| 2'-Deoxytubercidin SCHEMBL14294692 | 0.84 | METTL3 (0.57) | METTL3PRMT5ADK | |
| 2'-Deoxytubercidin SCHEMBL3229680 | 0.84 | METTL3 (0.57) | METTL3PRMT5ADK | |
| 2'-Deoxytubercidin SCHEMBL23982321 | 0.84 | METTL3 (0.57) | METTL3PRMT5ADK | |
| 2'-Deoxytubercidin SCHEMBL5918830 | 0.84 | METTL3 (0.57) | METTL3PRMT5ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | METTL3 4407/4885PRMT5 4089/4885POLB 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.